Codexis, Inc. (CDXS) stock
Close on Nov 11, 2026Market cap $106.92MP/E –Yield –
Codexis, Inc. grew revenue 66.9% to $88.34M over the twelve months to Sep 30, 2026. Free cash flow was -$12.14M. At the latest close the market valued the company at $106.92M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $106.92M
- P/E ratio
- –
- Price to sales
- 1.38
- Price to book
- 3.24
- Dividend yield
- –
- Free cash flow yield
- -11.39%
Fundamentals
- Revenue
- $88.34M
- Net income
- -$19.24M
- EPS, diluted
- -$0.20
- Free cash flow
- -$12.14M
- Book value per share
- $0.48
- Diluted shares
- 107M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.00
- Open
- $1.00
- Day's range
- $0.95 – $1.01
- Volume
- 1,667,547
- Average volume (20 days)
- 871,271
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 2.40
- 52-week range
- $0.95 – $2.98
- RSI (14 days)
- 32.2
- Volatility (1 year)
- 85.7%
- Relative volume
- 1.62×
- WACC
- 13.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CDXS | S&P 500 | Difference | CDXS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.8% | -2.4% | −28.3 pts | ||
| 3 months | -34.0% | -1.2% | −32.9 pts | ||
| Year to date | -40.1% | +12.3% | −52.4 pts | ||
| 1 year | -45.8% | +12.4% | −58.2 pts | ||
| 3 years | -41.2% | +78.8% | −120.0 pts | -16.2% | +21.4% |
| 5 years | -97.4% | +75.2% | −172.6 pts | -51.8% | +11.9% |
| 10 years | -81.0% | +311.1% | −392.1 pts | -15.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Codexis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Codexis
Industrial Organic Chemicals
Codexis, Inc. discovers, engineers, and supplies specialized enzymes and proteins to optimize the manufacturing of biopharmaceutical therapeutics. The company operates through two primary areas: its small molecule biocatalysis business and its ECO Synthesis platform. In biocatalysis, it designs custom enzymes that act as biocatalysts to improve synthesis efficiency, product purity, and yield for small-molecule drugs. Through its ECO Synthesis platform, the company provides enzymatic synthesis tools and contract process development services to support the production of RNA interference therapies, including small interfering RNA. Its customers include global pharmaceutical developers, biotechnology firms, and contract development and manufacturing organizations.
Company profile, executives and historyCodexis stock: common questions
What is Codexis's stock price?
CDXS closed at $0.98 on Nov 11, 2026, down 2.36% on the day. Over the past 52 weeks it traded between $0.95 and $2.98.
What is Codexis's market cap?
Codexis was worth $106.92M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CDXS's P/E ratio?
Codexis lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.20), so it has no meaningful P/E ratio.
How much revenue does Codexis make?
Codexis reported revenue of $88.34M for the twelve months to Sep 30, 2026, up 66.9% from a year earlier.
Does Codexis pay a dividend?
No. Codexis has not paid a cash dividend over the last twelve months.
When does Codexis report earnings next?
Codexis's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has CDXS stock performed over the past year?
Including dividends, CDXS returned -45.8% over the past year, against +12.4% for the S&P 500.
How many CDXS shares are sold short?
4M shares were sold short at the latest FINRA report, 4.11% of the float, or 4.9 days of average trading volume.
Who are Codexis's competitors?
Companies most similar to Codexis by business, industry and size include LNZA, FF, PLX, CNEY, GEVO.
See a number that looks wrong?